PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-7.66%
Revenue decline while Drug Manufacturers - Specialty & Generic median is 1.49%. Seth Klarman would investigate if market share loss is temporary.
4.54%
Cost growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.05%. Jim Chanos would check for structural cost disadvantages.
-35.70%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-30.36%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-34.39%
R&D reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
-32.37%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
26.62%
Marketing expense change of 26.62% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
3334.27%
Other expenses change of 3334.27% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
-15.52%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is 3.14%. Seth Klarman would investigate advantages.
-4.39%
Total costs reduction while Drug Manufacturers - Specialty & Generic median is 2.32%. Seth Klarman would investigate advantages.
-2.26%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-26.23%
D&A reduction while Drug Manufacturers - Specialty & Generic median is 1.50%. Seth Klarman would investigate efficiency.
65.77%
EBITDA change of 65.77% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
62.93%
Margin change of 62.93% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
20.21%
Operating income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
13.59%
Margin change of 13.59% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
341.00%
Other expenses change of 341.00% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify control.
100.42%
Income change of 100.42% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
100.46%
Margin change of 100.46% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-219.09%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
113.92%
Income change of 113.92% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
115.07%
Margin change of 115.07% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
99.57%
EPS change of 99.57% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
99.57%
Diluted EPS change of 99.57% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
2.42%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would check for issues.
2.42%
Diluted share change of 2.42% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.